Overview

Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2021-03-29
Target enrollment:
Participant gender:
Summary
This study is an open-label extension study to determine the long-term safety and tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study, APD811-003. Patients must have completed the APD811-003 study and must meet eligibility criteria for APD811-007.
Phase:
Phase 2
Details
Lead Sponsor:
Arena Pharmaceuticals
United Therapeutics